Benzinga

Benzinga

Benzinga

miércoles, agosto 19

Capricor Therapeutics Inc

CAPRNASDAQ
Trade with Public
Trade with Public
$7.08
-0.37-4.97%
al cierre: Aug 18, 5:00 PM EST
$7.06
-0.02-0.28%
After hour: 7:42 PM EST
Ganancias: Los beneficios de Q2 2026 se publicaron el jue ago 13th, después del cierre del mercado
Conferencia telefónica: La conferencia telefónica más reciente comenzó a las 4:30 p. m., hace 5 días
Haz clic para ver el webcast
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Capricor Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Capricor Therapeutics (CAPR).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

6Buy
3Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$34Upside to Avg. PT+375.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026Cantor FitzgeraldKristen KluskaUpgradeNeutral→Overweight$4→$28
Jul 31, 2026Jones TradingCatherine NovackDowngradeBuy→Hold—
More with Benzinga EdgeGet Access

Analyst Ratings News

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
Avi Kapoor

PRO
Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.
Benzinga Newsdesk

PRO
Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

Cantor Fitzgerald analyst Kristen Kluska downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $62 to $3.5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Capricor Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Capricor Therapeutics (NASDAQ:CAPR) from Buy to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $60 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved